|
Dec 8
|
BCLI: FDA Meeting Provides Clear Path for Planned Phase 3b Trial of NurOwn
|
|
Dec 7
|
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
|
|
Apr 24
|
BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer
|